LGALS9C: A Potential Drug Target and Biomarker (G654346)

Target Name: LGALS9C

NCBI ID: G654346

LGALS9C

LGALS9C: A Potential Drug Target and Biomarker

LGALS9C, also known as galectin-9, is a gene that encodes a protein known as galectin-9. Galectin-9 is a type of carbohydrate-binding protein that is expressed in various cell types, including epithelial, endothelial, and nervous cells. It is involved in cell adhesion, migration, and invasion, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LGALS9C has potential as a drug target or biomarker.

Drug Target Potential

LGALS9C has been identified as a potential drug target due to its involvement in a number of cellular processes that are associated with the development and progression of diseases. For example, LGALS9C has been shown to promote the growth and survival of cancer cells, and has been used as a model for cancer drug screening. Additionally, LGALS9C has been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, and has been shown to contribute to the progression of these conditions.

Biomarker Potential

In addition to its potential as a drug target, LGALS9C has also been identified as a potential biomarker for a number of diseases. For example, LGALS9C has been shown to be expressed in various types of cancer, and has been used as a biomarker for cancer diagnosis and treatment. Additionally, LGALS9C has been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, and has been shown to contribute to the progression of these conditions.

Expression and Functions

LGALS9C is a gene that encodes a protein known as galectin-9. This protein is involved in a number of cellular processes, including cell adhesion, migration, and invasion. It is a type of carbohydrate-binding protein that is expressed in various cell types, including epithelial, endothelial, and nervous cells.

One of the key functions of LGALS9C is its role in cell adhesion. This protein is involved in the formation of tight junctions, which are specialized barriers that maintain the integrity of epithelial cells. LGALS9C is thought to play a role in the formation of these barriers by interacting with the protein transmembrane protease (TMZ), which is involved in the formation of tight junctions.

In addition to its role in cell adhesion, LGALS9C is also involved in the regulation of cell migration and invasion. This protein is thought to play a role in the migration of cancer cells through the bloodstream, and has been shown to contribute to the development of cancer. Additionally, LGALS9C has been shown to contribute to the invasion of cancer cells into surrounding tissues, and is thought to play a role in the development of cancer.

Clinical Applications

As a potential drug target, LGALS9C has been the subject of a number of clinical trials aimed at inhibiting its activity. For example, researchers have developed a drug that targets LGALS9C and has shown to inhibit its activity in cell cultures. Additionally, researchers have used LGALS9C as a biomarker to predict the effectiveness of cancer treatments.

As a potential biomarker, LGALS9C has been used in a number of studies to predict the outcomes of cancer treatments. For example, researchers have used LGALS9C as a biomarker to predict the recurrence of breast cancer in women who have undergone lumpectomy. Additionally, LGALS9C has been used as a biomarker to predict the outcomes of radiation therapy in

Protein Name: Galectin 9C

Functions: Binds galactosides

The "LGALS9C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGALS9C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets